{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+Chloride+Injection+USP+%28Saline%29%29", "query": { "intervention": "Placebo (0.9% Sodium Chloride Injection USP (Saline))" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 98, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+Chloride+Injection+USP+%28Saline%29%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T04:41:21.811Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04380324", "title": "A Study of NKTR-358 (LY3471851) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY3471851", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 100, "start_date": "2017-03-19", "completion_date": "2019-01-20", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380324" }, { "nct_id": "NCT03409276", "title": "Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "gp120 (A,B,C,A/E) Protein Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2018-03-16", "completion_date": "2020-10-22", "has_results": true, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409276" }, { "nct_id": "NCT06546709", "title": "DMID 23-0015; Lassa Fever CVD 1000", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lassa Fever" ], "interventions": [ { "name": "LASSARAB+ aPHAD-SEat 700rU", "type": "BIOLOGICAL" }, { "name": "HDCV Comparator", "type": "BIOLOGICAL" }, { "name": "Normal Saline Placebo", "type": "OTHER" }, { "name": "LASSARAB+ aPHAD-SEat 1400rU", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Wilbur Chen, MD, MS", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 54, "start_date": "2025-01-13", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546709" }, { "nct_id": "NCT01285518", "title": "Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "PF-05231023", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "30 Years to 65 Years" }, "enrollment_count": 84, "start_date": "2011-02", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2016-11-18", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 5, "location_summary": "Chula Vista, California • Fort Meyers, Florida • Miami, Florida + 2 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285518" }, { "nct_id": "NCT04498117", "title": "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Ovarian Epithelial", "Ovarian Neoplasms", "Ovarian Cancer", "Ovarian Serous Adenocarcinoma", "Fallopian Tube Neoplasms", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Peritoneal Cancer", "Peritoneal Carcinoma", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Oregovomab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CanariaBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 615, "start_date": "2020-08-25", "completion_date": "2028-08-26", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 81, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04498117" }, { "nct_id": "NCT03395704", "title": "A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Hemochromatosis" ], "interventions": [ { "name": "LJPC-401", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "La Jolla Pharmaceutical Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-11-29", "completion_date": "2019-10-28", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 18, "location_summary": "North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rialto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03395704" }, { "nct_id": "NCT00195312", "title": "Study Evaluating Vaccine in Adults With HIV", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 gag DNA (formulated with bupivacaine)", "type": "BIOLOGICAL" }, { "name": "IL-15 DNA (formulated with bupivacaine)", "type": "BIOLOGICAL" }, { "name": "IL-12 DNA (formulated with bupivacaine)", "type": "BIOLOGICAL" }, { "name": "Sodium chloride injection USP (0.9%)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 91, "start_date": "2005-08", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2007-12-05", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00195312" }, { "nct_id": "NCT04589403", "title": "1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "OPT101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Op-T LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 14, "start_date": "2021-02-18", "completion_date": "2021-09-27", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 1, "location_summary": "Centennial, Colorado", "locations": [ { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589403" }, { "nct_id": "NCT07473752", "title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Phase 1 First-in-human Study Involving Healthy Subjects" ], "interventions": [ { "name": "TNX-1500", "type": "DRUG" }, { "name": "Placebo: USP 0.9% sterile saline for injection", "type": "DRUG" }, { "name": "Keyhole Limpet Hemocyanin (KLH)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 26, "start_date": "2023-07-18", "completion_date": "2024-02-22", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07473752" }, { "nct_id": "NCT02743455", "title": "A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Yellow Fever", "Yellow Fever Immunisation" ], "interventions": [ { "name": "ISA-720", "type": "DRUG" }, { "name": "MVA Smallpox Vaccine", "type": "BIOLOGICAL" }, { "name": "MVA-BN Yellow Fever Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "YF Vax 17D Strain", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 92, "start_date": "2016-07-05", "completion_date": "2018-03-22", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-08T04:41:21.811Z", "location_count": 2, "location_summary": "Iowa City, Iowa • St Louis, Missouri", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743455" } ] }